Paysign Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Paysign heeft de winst zien groeien met een gemiddeld jaarlijks percentage van 69.9%, terwijl de Diversified Financial-industrie de winst zag groeien met 13.5% per jaar. De inkomsten zijn gegroeid met een gemiddeld jaarlijks percentage van 25.9%. Het rendement op eigen vermogen van Paysign is 18.9%, en het heeft een nettomarge van 11.4%.
Belangrijke informatie
69.87%
Groei van de winst
70.07%
Groei van de winst per aandeel
| Diversified Financial Groei van de industrie | 6.15% |
| Inkomstengroei | 25.89% |
| Rendement op eigen vermogen | 18.91% |
| Nettomarge | 11.37% |
| Laatste winstupdate | 31 Mar 2026 |
Recente prestatie-updates uit het verleden
Recent updates
PAYS: Higher Margin Guidance And Premium P/E Framework Will Drive Repricing
Analysts have nudged their fair value estimate for Paysign up from $12.00 to $12.75, citing updated assumptions around growth, margins, and future P/E that fed into the latest price target increase highlighted in recent Street research. Analyst Commentary Recent Street research highlights a more constructive tone around Paysign, with bullish analysts pointing to the refreshed fair value estimate and updated assumptions as key supports for their views.PAYS: Higher Margin Outlook Will Support Repricing On Updated Profitability Assumptions
Analysts have raised their price target on Paysign by $1 to $12, citing updated assumptions around growth, profitability, discount rate and future P/E as the main drivers of this change. Analyst Commentary Bullish analysts are highlighting the recent price target move to US$12 as a sign of growing confidence in Paysign's outlook, with updated assumptions around growth, profitability, discount rate and future P/E at the core of their thesis.PAYS: Higher Margin Outlook And Raised P/E Assumption Will Support Repricing
Analysts lifted their Paysign price target by $1 to reflect slightly higher modeled revenue growth, modestly stronger profit margins, and an adjusted future P/E assumption, all under broadly consistent fair value and discount rate inputs. Analyst Commentary Bullish analysts framing the recent price target move highlight that the updated P/E assumption and slightly higher modeled revenue and margins support a higher fair value range for Paysign, while keeping discount rate inputs broadly consistent.PAYS: Higher Profit Margin Outlook Will Support More Constructive Share Repricing
The analyst price target for Paysign has increased from $9.50 to $12.00, with analysts citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as key drivers of the change. Analyst Commentary Recent research points to a more constructive view on Paysign, with bullish analysts updating their models to reflect what they see as improved fair value assumptions and a more supportive outlook for key valuation inputs such as discount rate, revenue growth, profit margin and future P/E.The Price Is Right For Paysign, Inc. (NASDAQ:PAYS) Even After Diving 27%
Paysign, Inc. ( NASDAQ:PAYS ) shareholders that were waiting for something to happen have been dealt a blow with a 27...Paysign, Inc. Just Beat EPS By 100%: Here's What Analysts Think Will Happen Next
Paysign, Inc. ( NASDAQ:PAYS ) just released its quarterly report and things are looking bullish. The company beat...Paysign: Gaining Traction In The Patient Affordability Space Into 2026 (Hold)
Summary Paysign posted strong Q2 2025 results, with 33% YoY revenue growth and robust Pharma segment momentum, driven by US tariffs and new client wins. PAYS is rated a hold, as the stock trades at fair value ($5.83), despite expected high demand for co-payment cards and expanded patient affordability programs. Pharma segment revenue surged 189% YoY, offsetting a 4.7% YoY decline in the core Plasma segment, which faces ongoing headwinds from transitioning centers. While PAYS benefits from industry tailwinds and guidance consistency, risks remain due to Plasma's weakness and Pharma revenues still lagging Plasma's overall contribution. Read the full article on Seeking AlphaPaysign, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NasdaqCM:PAYS 1 Year Share Price vs Fair Value Explore Paysign's Fair Values from the Community and select yours One of...
Digital Payment Solutions Will Expand Healthcare Access Further
Analysts maintain a positive outlook on Paysign due to ongoing growth in its Patient Affordability segment, confidence in its pharmaceutical pipeline, and scalable model, resulting in no change to the consensus price target, which remains at $9.10. Analyst Commentary Bullish analysts highlight a strong outlook for Paysign's Patient Affordability segment, especially within the pharmaceutical industry.Paysign, Inc.'s (NASDAQ:PAYS) 28% Price Boost Is Out Of Tune With Earnings
Those holding Paysign, Inc. ( NASDAQ:PAYS ) shares would be relieved that the share price has rebounded 28% in the last...Paysign, Inc.'s (NASDAQ:PAYS) Share Price Not Quite Adding Up
With a median price-to-earnings (or "P/E") ratio of close to 18x in the United States, you could be forgiven for...Here's Why Paysign (NASDAQ:PAYS) Has Caught The Eye Of Investors
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Paysign Is A Leader In Fintech Healthcare Payments With Durable Profitable Growth
Summary Paysign is a promising microcap payment processing company with a projected 42% annualized return, potentially reaching $19/share by 2030 from $3.30/share today. The company excels in two primary sectors: plasma payment processing and pharma patient affordability, both offering significant growth and high gross margins. PAYS's plasma business boasts a 40% market share with steady 10-15% annual growth, while the pharma segment is expected to surpass plasma with rapid expansion. Risks include increased competition, potential loss of key customers, and limited financial resources, but catalysts like market share gains and acquisition potential bolster the investment thesis. Read the full article on Seeking Alpha
Rapid Growth In Patient Affordability Market Fuels Optimism Despite Looming Margin Pressures
The expansion into the patient affordability segment and significant client growth, like AstraZeneca, indicates a promising area for revenue and earnings increases.Do Paysign's (NASDAQ:PAYS) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Paysign, Inc. (NASDAQ:PAYS) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Paysign, Inc. ( NASDAQ:PAYS ) shareholders are probably feeling a little disappointed, since its shares fell 7.1% to...Paysign: Expect Rapid Growth In Its Pharma Business
Summary Shares have risen sharply this year, reflecting solid business performance. Its pharma segment is experiencing exceptional growth and has a long runway for continued expansion. My valuation model indicates that shares have limited upside. Read the full article on Seeking AlphaPaysign, Inc. (NASDAQ:PAYS) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Paysign, Inc. ( NASDAQ:PAYS ) shares have continued their recent momentum with a 30% gain in the last month alone. The...Here's Why We Think PaySign (NASDAQ:PAYS) Is Well Worth Watching
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Revenues Tell The Story For PaySign, Inc. (NASDAQ:PAYS)
PaySign, Inc.'s ( NASDAQ:PAYS ) price-to-sales (or "P/S") ratio of 3.4x may not look like an appealing investment...Opbrengsten en kosten
Hoe Paysign geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 26 | 91 | 10 | 35 | 0 |
| 31 Dec 25 | 82 | 8 | 33 | 0 |
| 30 Sep 25 | 75 | 8 | 31 | 0 |
| 30 Jun 25 | 69 | 7 | 29 | 0 |
| 31 Mar 25 | 64 | 6 | 27 | 0 |
| 31 Dec 24 | 58 | 4 | 25 | 0 |
| 30 Sep 24 | 56 | 8 | 24 | 0 |
| 30 Jun 24 | 54 | 8 | 22 | 0 |
| 31 Mar 24 | 50 | 7 | 22 | 0 |
| 31 Dec 23 | 47 | 6 | 21 | 0 |
| 30 Sep 23 | 44 | 2 | 20 | 0 |
| 30 Jun 23 | 42 | 1 | 20 | 0 |
| 31 Mar 23 | 40 | 1 | 18 | 0 |
| 31 Dec 22 | 38 | 1 | 18 | 0 |
| 30 Sep 22 | 36 | 0 | 18 | 0 |
| 30 Jun 22 | 33 | -1 | 17 | 0 |
| 31 Mar 22 | 31 | -1 | 17 | 0 |
| 31 Dec 21 | 29 | -3 | 16 | 0 |
| 30 Sep 21 | 28 | -7 | 15 | 0 |
| 30 Jun 21 | 20 | -13 | 15 | 0 |
| 31 Mar 21 | 20 | -12 | 15 | 0 |
| 31 Dec 20 | 24 | -9 | 15 | 0 |
| 30 Sep 20 | 27 | -3 | 14 | 0 |
| 30 Jun 20 | 36 | 6 | 13 | 0 |
| 31 Mar 20 | 38 | 8 | 13 | 0 |
| 31 Dec 19 | 35 | 7 | 12 | 0 |
| 30 Sep 19 | 32 | 6 | 11 | 0 |
| 30 Jun 19 | 29 | 4 | 10 | 0 |
| 31 Mar 19 | 26 | 3 | 9 | 0 |
| 31 Dec 18 | 23 | 3 | 8 | 0 |
| 30 Sep 18 | 21 | 2 | 6 | 0 |
| 30 Jun 18 | 19 | 2 | 6 | 0 |
| 31 Mar 18 | 17 | 2 | 5 | 0 |
| 31 Dec 17 | 15 | 2 | 4 | 0 |
| 30 Sep 17 | 14 | 2 | 3 | 0 |
| 30 Jun 17 | 12 | 2 | 3 | 0 |
| 31 Mar 17 | 11 | 2 | 3 | 0 |
| 31 Dec 16 | 10 | 1 | 3 | 0 |
| 30 Sep 16 | 10 | 1 | 3 | 0 |
| 30 Jun 16 | 9 | -2 | 3 | 0 |
| 31 Mar 16 | 9 | -2 | 4 | 0 |
| 31 Dec 15 | 8 | -2 | 4 | 0 |
| 30 Sep 15 | 11 | 0 | 4 | 0 |
| 30 Jun 15 | 11 | 3 | 3 | 0 |
Kwaliteitswinsten: PAYS heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (11.4%) PAYS } zijn hoger dan vorig jaar (9.6%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: PAYS is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 69.9% per jaar laten groeien.
Versnelling van de groei: De winstgroei van PAYS over het afgelopen jaar ( 70.8% ) overtreft het 5-jarig gemiddelde ( 69.9% per jaar).
Winst versus industrie: De winstgroei PAYS over het afgelopen jaar ( 70.8% ) overtrof de Diversified Financial -sector 8.6%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 18.9% ) van PAYS wordt als laag beschouwd.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/27 07:56 |
| Aandelenkoers aan het einde van de dag | 2026/05/27 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Paysign, Inc. wordt gevolgd door 6 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Gary Prestopino | Barrington Research Associates, Inc. |
| Austin Moldow | Canaccord Genuity |
| Peter Heckmann | D.A. Davidson & Co. |